Latest Non-nucleoside reverse transcriptase inhibitors Stories
MEXICO CITY, Aug. 5 /PRNewswire/ -- New phase IIb data from Tibotec Pharmaceuticals Ltd.
YARDLEY, Pa., July 17 /PRNewswire/ -- Tibotec Pharmaceuticals Ltd. announced today that two major phase III efficacy trials examining TMC278, its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in treatment-naive adults with HIV-1, are now recruiting patients.
CytoDyn, Inc. (Pink Sheets: CYDY) has begun GMP manufacturing and humanization of Cytolin(C), a monoclonal antibody that uses the human immune system to control HIV infection.
WASHINGTON (Reuters) - A three-in-one AIDS pill officials hope will make it easier for patients to stick with their treatments won U.S. clearance on Friday for use in a global relief plan. The drug, made by India's Aurobindo Pharma Ltd., received tentative Food and Drug Administration approval.
WASHINGTON (Reuters) - India's Aurobindo Pharma Ltd. won tentative U.S. approval on Friday to sell a three-in-one HIV-fighting pill, a decision that makes the drug available for purchase under a global AIDS relief plan.
NEW YORK (Reuters Health) - Higher blood levels of the anti-HIV drug efavirenz confer an increased risk of mental problems, Spanish researchers report.
Two new studies support the hypothesis that combination antiretroviral drug therapy may reduce the risk of mother-to-child HIV transmission through breastfeeding, findings that could have significant implications in the developing world. Researchers in the first study found mothers pass antiretroviral medications on to their breastfeeding infants in concentrations high enough to prevent infection. The second study showed levels of HIV RNA in breast milk are lower in mothers taking...